| 1 | Conquering Overtreatment of DCIS: Lessons from PRECISION | 25.1 | 4 | Citations (PDF) |
| 2 | A morphometric signature to identify ductal carcinoma in situ with a low risk of progression | 6.5 | 1 | Citations (PDF) |
| 3 | Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry | 2.0 | 6 | Citations (PDF) |
| 4 | Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features | 9.7 | 2 | Citations (PDF) |
| 5 | Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands between 1989 and 2021: Time trends and the association with tumour grade | 4.9 | 0 | Citations (PDF) |
| 6 | Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment | 62.1 | 62 | Citations (PDF) |
| 7 | Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer | 3.6 | 7 | Citations (PDF) |
| 8 | Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade | 5.5 | 3 | Citations (PDF) |
| 9 | An early economic evaluation of active surveillance for low-risk ductal carcinoma
in situ | 2.3 | 1 | Citations (PDF) |
| 10 | Tumour-educated platelets for breast cancer detection: biological and technical insights | 5.5 | 19 | Citations (PDF) |
| 11 | Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers | 13.7 | 38 | Citations (PDF) |
| 12 | High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial | 6.4 | 4 | Citations (PDF) |
| 13 | Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer | 6.6 | 13 | Citations (PDF) |
| 14 | The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population | 2.3 | 6 | Citations (PDF) |
| 15 | Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis | 3.7 | 10 | Citations (PDF) |
| 16 | Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study | 2.0 | 14 | Citations (PDF) |
| 17 | Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features | 8.7 | 41 | Citations (PDF) |
| 18 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes | 4.7 | 28 | Citations (PDF) |
| 19 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients | 27.4 | 427 | Citations (PDF) |
| 20 | Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments | 6.8 | 15 | Citations (PDF) |
| 21 | Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology | 4.9 | 3 | Citations (PDF) |
| 22 | Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance | 6.4 | 35 | Citations (PDF) |
| 23 | Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer | 25.2 | 86 | Citations (PDF) |
| 24 | Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review | 3.8 | 11 | Citations (PDF) |
| 25 | Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival | 2.3 | 10 | Citations (PDF) |
| 26 | Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer | 4.8 | 42 | Citations (PDF) |
| 27 | Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers | 6.8 | 23 | Citations (PDF) |
| 28 | Learning to distinguish progressive and non-progressive ductal carcinoma in situ | 60.7 | 46 | Citations (PDF) |
| 29 | Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence? | 2.3 | 20 | Citations (PDF) |
| 30 | Variability in grading of ductal carcinoma in situ among an international group of pathologists | 3.3 | 38 | Citations (PDF) |
| 31 | Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ | 6.4 | 24 | Citations (PDF) |
| 32 | The Way of the Future: Personalizing Treatment Plans Through Technology | 4.4 | 23 | Citations (PDF) |
| 33 | Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study | 24.1 | 89 | Citations (PDF) |
| 34 | Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer | 2.3 | 16 | Citations (PDF) |
| 35 | Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience | 2.3 | 12 | Citations (PDF) |
| 36 | Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer | 14.3 | 128 | Citations (PDF) |
| 37 | Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer | 2.4 | 1 | Citations (PDF) |
| 38 | Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists | 3.8 | 17 | Citations (PDF) |
| 39 | Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast | 5.5 | 17 | Citations (PDF) |
| 40 | Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic | 2.8 | 61 | Citations (PDF) |
| 41 | IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women | 6.4 | 3 | Citations (PDF) |
| 42 | Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients | 2.3 | 1 | Citations (PDF) |
| 43 | Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients | 1.5 | 26 | Citations (PDF) |
| 44 | Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index | 3.6 | 9 | Citations (PDF) |
| 45 | Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study | 2.3 | 28 | Citations (PDF) |
| 46 | BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer | 4.7 | 9 | Citations (PDF) |
| 47 | Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk | 14.3 | 51 | Citations (PDF) |
| 48 | Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer | 6.4 | 14 | Citations (PDF) |
| 49 | The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands | 24.1 | 123 | Citations (PDF) |
| 50 | Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression | 8.7 | 56 | Citations (PDF) |
| 51 | Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial | 1.5 | 50 | Citations (PDF) |
| 52 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement | 70.7 | 358 | Citations (PDF) |
| 53 | Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer | 3.8 | 31 | Citations (PDF) |
| 54 | Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03) | 2.0 | 22 | Citations (PDF) |
| 55 | The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review | 2.3 | 8 | Citations (PDF) |
| 56 | Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification | 4.1 | 33 | Citations (PDF) |
| 57 | Famrisc, a RCT comparing mammography with MRI in screening for familial risk | 0.9 | 0 | Citations (PDF) |
| 58 | Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study | 2.3 | 22 | Citations (PDF) |
| 59 | Ductal carcinoma in situ: to treat or not to treat, that is the question | 5.5 | 279 | Citations (PDF) |
| 60 | Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related? | 2.8 | 9 | Citations (PDF) |
| 61 | Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping | 4.4 | 217 | Citations (PDF) |
| 62 | Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES | 2.3 | 5 | Citations (PDF) |
| 63 | MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial | 27.4 | 163 | Citations (PDF) |
| 64 | Utility of diagnostic breast excision biopsies during two decades of screening mammography | 2.3 | 6 | Citations (PDF) |
| 65 | Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore | 6.8 | 22 | Citations (PDF) |
| 66 | EZH2 Is Overexpressed in
BRCA1
-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy | 6.8 | 43 | Citations (PDF) |
| 67 | Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses | 1.1 | 62 | Citations (PDF) |
| 68 | Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS | 3.5 | 18 | Citations (PDF) |
| 69 | Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
In Situ
—A Nested Case–Control Study | 6.8 | 43 | Citations (PDF) |
| 70 | Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ | 4.6 | 72 | Citations (PDF) |
| 71 | Perfusion in the contralateral breast on preoperative MRI may complement ER-pathway activity from the index tumor to stratify outcome of endocrine therapy for early-stage invasive breast cancer | 4.9 | 1 | Citations (PDF) |
| 72 | PO-467 Integrative modelling to understand and predict cancer drug response | 5.3 | 0 | Citations (PDF) |
| 73 | PO-331 Understanding DCIS initiation and progression using tumouroid and mouse models | 5.3 | 0 | Citations (PDF) |
| 74 | PO-069 Clinical and histological risk factors for subsequent in situ lesions after a primary diagnosis of ductal carcinoma in situ | 5.3 | 0 | Citations (PDF) |
| 75 | PO-070 Identification of risk factors for subsequent invasive breast cancer after primary DCIS by transcriptomic profiling | 5.3 | 0 | Citations (PDF) |
| 76 | Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial | 27.4 | 387 | Citations (PDF) |
| 77 | Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) | 4.9 | 16 | Citations (PDF) |
| 78 | FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome | 4.1 | 22 | Citations (PDF) |
| 79 | Breast cancer–related deaths according to grade in ductal carcinoma in situ: A Dutch population–based study on patients diagnosed between 1999 and 2012 | 4.9 | 18 | Citations (PDF) |
| 80 | Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot | 2.9 | 7 | Citations (PDF) |
| 81 | Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study | 2.5 | 5 | Citations (PDF) |
| 82 | PO-337 Single cell mRNA sequencing reveals the presence of the gene expression signature of all major molecular subtypes in individual breast cancers | 5.3 | 2 | Citations (PDF) |
| 83 | PO-498 Spliced RNA panels from tumor-educated platelets (TEP) enable detection of early breast cancer | 5.3 | 1 | Citations (PDF) |
| 84 | The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors | 2.9 | 13 | Citations (PDF) |
| 85 | Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study | 4.9 | 22 | Citations (PDF) |
| 86 | Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review | 5.0 | 26 | Citations (PDF) |
| 87 | MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy | 2.3 | 41 | Citations (PDF) |
| 88 | Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women | 4.6 | 73 | Citations (PDF) |
| 89 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 25.2 | 405 | Citations (PDF) |
| 90 | The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study | 2.3 | 54 | Citations (PDF) |
| 91 | Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials | 2.3 | 100 | Citations (PDF) |
| 92 | Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study | 1.9 | 13 | Citations (PDF) |
| 93 | Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma | 25.2 | 72 | Citations (PDF) |
| 94 | The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study | 4.7 | 17 | Citations (PDF) |
| 95 | Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer | 2.8 | 13 | Citations (PDF) |
| 96 | Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS) | 2.3 | 140 | Citations (PDF) |
| 97 | BRCA1
-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency | 6.8 | 22 | Citations (PDF) |
| 98 | Enrichment of high-grade tumors in breast cancer gene expression studies | 2.3 | 5 | Citations (PDF) |
| 99 | Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes | 2.3 | 22 | Citations (PDF) |
| 100 | Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients | 2.3 | 8 | Citations (PDF) |
| 101 | Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer | 6.8 | 11 | Citations (PDF) |
| 102 | Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer | 2.4 | 16 | Citations (PDF) |
| 103 | An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer | 2.9 | 12 | Citations (PDF) |
| 104 | Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer | 4.6 | 200 | Citations (PDF) |
| 105 | Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women | 2.3 | 63 | Citations (PDF) |
| 106 | Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer | 3.4 | 175 | Citations (PDF) |
| 107 | High
XIST
and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a
BRCA1
-like Breast Cancer | 1.9 | 48 | Citations (PDF) |
| 108 | Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy | 2.3 | 60 | Citations (PDF) |
| 109 | Genetic predisposition to ductal carcinoma in situ of the breast | 4.7 | 54 | Citations (PDF) |
| 110 | Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I–III Breast Cancer: Comparison With Standard PET/CT | 4.1 | 46 | Citations (PDF) |
| 111 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups | 4.7 | 69 | Citations (PDF) |
| 112 | Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer | 4.7 | 23 | Citations (PDF) |
| 113 | The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening | 4.7 | 81 | Citations (PDF) |
| 114 | Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers | 2.9 | 18 | Citations (PDF) |
| 115 | Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period | 2.3 | 48 | Citations (PDF) |
| 116 | Tumour-specific proline vulnerability uncovered by differential ribosome codon reading | 37.9 | 265 | Citations (PDF) |
| 117 | Defining hip pain trajectories in early symptomatic hip osteoarthritis – 5 year results from a nationwide prospective cohort study (CHECK) | 5.5 | 33 | Citations (PDF) |
| 118 | Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients | 4.6 | 413 | Citations (PDF) |
| 119 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium | 3.3 | 26 | Citations (PDF) |
| 120 | Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response | 4.7 | 68 | Citations (PDF) |
| 121 | The Use of Mass Spectrometry Imaging to Predict Treatment Response of Patient-Derived Xenograft Models of Triple-Negative Breast Cancer | 3.4 | 28 | Citations (PDF) |
| 122 | The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure | 2.3 | 6 | Citations (PDF) |
| 123 | Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries | 2.3 | 75 | Citations (PDF) |
| 124 | Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration | 9.9 | 214 | Citations (PDF) |
| 125 | First results of the preoperative accelerated partial breast irradiation (PAPBI) trial | 2.0 | 71 | Citations (PDF) |
| 126 | Retrospective analysis of metastatic behaviour of breast cancer subtypes | 2.3 | 158 | Citations (PDF) |
| 127 | Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study | 4.9 | 347 | Citations (PDF) |
| 128 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis | 7.1 | 58 | Citations (PDF) |
| 129 | Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach | 2.3 | 22 | Citations (PDF) |
| 130 | Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups | 2.3 | 20 | Citations (PDF) |
| 131 | Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases | 2.3 | 9 | Citations (PDF) |
| 132 | Margin Assessment in Breast Cancer Lumpectomy Specimens with Infrared Diffuse Reflectance Spectroscopy(Drs) | 9.9 | 1 | Citations (PDF) |
| 133 | Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype | 2.3 | 67 | Citations (PDF) |
| 134 | Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study | 2.3 | 36 | Citations (PDF) |
| 135 | Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases | 2.9 | 36 | Citations (PDF) |
| 136 | Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast | 3.2 | 45 | Citations (PDF) |
| 137 | Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis | 2.3 | 58 | Citations (PDF) |
| 138 | Radio-guided seed localization for breast cancer excision | 1.1 | 8 | Citations (PDF) |
| 139 | Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes | 8.6 | 37 | Citations (PDF) |
| 140 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | 37.9 | 804 | Citations (PDF) |
| 141 | Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment | 4.7 | 48 | Citations (PDF) |
| 142 | Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy | 2.8 | 19 | Citations (PDF) |
| 143 | 82. Margin assessment in breast cancer lumpectomy specimens with infra-red diffuse reflectance spectroscopy (DRS) | 0.9 | 0 | Citations (PDF) |
| 144 | Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy | 5.5 | 50 | Citations (PDF) |
| 145 | Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms | 2.3 | 22 | Citations (PDF) |
| 146 | PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients | 4.7 | 60 | Citations (PDF) |
| 147 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy | 4.7 | 102 | Citations (PDF) |
| 148 | MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue | 2.5 | 98 | Citations (PDF) |
| 149 | Regulation of TRAIL receptor expression by -catenin in colorectal tumours | 2.8 | 14 | Citations (PDF) |
| 150 | Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values | 2.3 | 54 | Citations (PDF) |
| 151 | A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples | 3.3 | 58 | Citations (PDF) |
| 152 | Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response | 2.3 | 107 | Citations (PDF) |
| 153 | Guiding Breast-Conserving Surgery in Patients After Neoadjuvant Systemic Therapy for Breast Cancer: A Comparison of Radioactive Seed Localization with the ROLL Technique | 2.3 | 70 | Citations (PDF) |
| 154 | A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study | 4.3 | 209 | Citations (PDF) |
| 155 | Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer | 5.5 | 20 | Citations (PDF) |
| 156 | Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla | 2.3 | 50 | Citations (PDF) |
| 157 | Platform comparisons for identification of breast cancers with a BRCA-like copy number profile | 2.3 | 20 | Citations (PDF) |
| 158 | Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer | 4.0 | 11 | Citations (PDF) |
| 159 | Optical sensing for tumor detection in the liver | 0.9 | 59 | Citations (PDF) |
| 160 | Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy? | 2.8 | 4 | Citations (PDF) |
| 161 | Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer | 2.3 | 30 | Citations (PDF) |
| 162 | Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy | 2.6 | 69 | Citations (PDF) |
| 163 | Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers | 5.5 | 200 | Citations (PDF) |
| 164 | FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer | 2.3 | 84 | Citations (PDF) |
| 165 | Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing | 4.9 | 115 | Citations (PDF) |
| 166 | Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient | 9.9 | 53 | Citations (PDF) |
| 167 | Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study | 1.9 | 55 | Citations (PDF) |
| 168 | Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy | 5.5 | 57 | Citations (PDF) |
| 169 | Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’” | 2.3 | 1 | Citations (PDF) |
| 170 | Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy | 9.9 | 32 | Citations (PDF) |
| 171 | Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors | 3.8 | 51 | Citations (PDF) |
| 172 | Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: Potential relevance for MRI-guided localized therapy | 2.0 | 15 | Citations (PDF) |
| 173 | Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach | 4.7 | 53 | Citations (PDF) |
| 174 | Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer | 2.3 | 108 | Citations (PDF) |
| 175 | 443. Diffuse Reflectance Spectroscopy - a New Guidance Tool for Improvement of Biopsy Procedures in Lung Malignancies | 0.9 | 0 | Citations (PDF) |
| 176 | 235. Diffuse reflectance spectroscopy – Towards clinical application in breast cancer | 0.9 | 0 | Citations (PDF) |
| 177 | Diffuse Reflectance Spectroscopy: A New Guidance Tool for Improvement of Biopsy Procedures in Lung Malignancies | 2.8 | 59 | Citations (PDF) |
| 178 | Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy | 0.9 | 11 | Citations (PDF) |
| 179 | 185. Innovative optical technology for tumor detection in the liver | 0.9 | 0 | Citations (PDF) |
| 180 | Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy | 5.5 | 92 | Citations (PDF) |
| 181 | Diffuse Reflectance Spectroscopy; Towards Clinical Application in Breast Cancer | 9.9 | 0 | Citations (PDF) |
| 182 | Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases | 4.0 | 90 | Citations (PDF) |
| 183 | MRI of the breast in patients with DCIS to exclude the presence of invasive disease | 3.6 | 30 | Citations (PDF) |
| 184 | Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis | 3.6 | 58 | Citations (PDF) |
| 185 | Prevalence and predictors of health care use in patients with early hip or knee osteoarthritis: two-year follow-up data from the CHECK cohort | 5.5 | 25 | Citations (PDF) |
| 186 | SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer | 2.3 | 59 | Citations (PDF) |
| 187 | Diffuse reflectance spectroscopy: towards clinical application in breast cancer | 2.3 | 65 | Citations (PDF) |
| 188 | Is DCIS Breast Cancer, and How Do I Treat it? | 3.9 | 46 | Citations (PDF) |
| 189 | Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity | 13.7 | 96 | Citations (PDF) |
| 190 | Immunohistochemical Detection of the CXCR4 Expression in Tumor Tissue Using the Fluorescent Peptide Antagonist Ac-TZ14011-FITC | 3.6 | 18 | Citations (PDF) |
| 191 | Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions | 4.9 | 21 | Citations (PDF) |
| 192 | Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples | 2.8 | 84 | Citations (PDF) |
| 193 | The
CYP2C19*2
Genotype Predicts Tamoxifen Treatment Outcome in Advanced Breast Cancer Patients | 1.5 | 45 | Citations (PDF) |
| 194 | Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness | 4.7 | 78 | Citations (PDF) |
| 195 | 282 AVOIDANCE OF ACTIVITIES IN EARLY SYMPTOMATIC KNEE OSTEOARTHRITIS: RESULTS FROM THE CHECK COHORT | 5.5 | 0 | Citations (PDF) |
| 196 | 285 IDENTIFYING PAIN PHENOTYPES IN EARLY SYMPTOMATIC OA; DATA FROM THE CHECK STUDY (COHORT HIP & COHORT KNEE) | 5.5 | 0 | Citations (PDF) |
| 197 | Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands | 2.3 | 41 | Citations (PDF) |
| 198 | Genomic signature of BRCA1 deficiency in sporadic basal‐like breast tumors | 3.0 | 55 | Citations (PDF) |
| 199 | Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600 nm: comparison of classification methods | 2.3 | 143 | Citations (PDF) |
| 200 | HER2 gene amplification in patients with breast cancer with equivocal IHC results | 1.7 | 31 | Citations (PDF) |
| 201 | Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy | 9.9 | 72 | Citations (PDF) |
| 202 | Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice | 2.0 | 127 | Citations (PDF) |
| 203 | An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients | 9.9 | 161 | Citations (PDF) |
| 204 | Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics | 2.3 | 81 | Citations (PDF) |
| 205 | Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers | 4.6 | 81 | Citations (PDF) |
| 206 | MRI-Model to Guide the Surgical Treatment in Breast Cancer Patients After Neoadjuvant Chemotherapy | 4.6 | 61 | Citations (PDF) |
| 207 | Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature | 2.3 | 66 | Citations (PDF) |
| 208 | The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy | 2.3 | 120 | Citations (PDF) |
| 209 | A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results | 2.3 | 40 | Citations (PDF) |
| 210 | 285 SELF-REPORTED COMORBIDITY AND HEALTH STATUS IN EARLY OA: THE CHECK STUDY | 5.5 | 1 | Citations (PDF) |
| 211 | Symptomatic carrier of haemophilia B Leyden: a case report | 1.9 | 1 | Citations (PDF) |
| 212 | Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature | 5.5 | 66 | Citations (PDF) |
| 213 | Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies | 8.0 | 834 | Citations (PDF) |
| 214 | The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment | 9.9 | 59 | Citations (PDF) |
| 215 | Aggressiveness of ‘true’ interval invasive ductal carcinomas of the breast in postmenopausal women | 4.8 | 13 | Citations (PDF) |
| 216 | Receptor conversion in distant breast cancer metastases | 4.7 | 207 | Citations (PDF) |
| 217 | The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques | 0.9 | 99 | Citations (PDF) |
| 218 | Molecular subtyping of breast cancer: ready to use? | 27.4 | 17 | Citations (PDF) |
| 219 | A simple system for grading the response of breast cancer to neoadjuvant chemotherapy | 9.9 | 48 | Citations (PDF) |
| 220 | Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma | 2.3 | 54 | Citations (PDF) |
| 221 | Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH | 2.3 | 48 | Citations (PDF) |
| 222 | Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1) | 1.0 | 19 | Citations (PDF) |
| 223 | CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative | 6.9 | 123 | Citations (PDF) |
| 224 | 298 CHECK COHORT: RELATIONSHIP BETWEEN COMORBIDITY AND CLINICAL STATUS IN EARLY OA | 5.5 | 0 | Citations (PDF) |
| 225 | Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer | 4.9 | 54 | Citations (PDF) |
| 226 | Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer | 4.8 | 33 | Citations (PDF) |
| 227 | Microarray methods to identify factors determining breast cancer progression: Potentials, limitations, and challenges | 5.0 | 19 | Citations (PDF) |
| 228 | Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer | 4.9 | 57 | Citations (PDF) |
| 229 | Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: Lasting local control and acceptable morbidity | 0.9 | 13 | Citations (PDF) |
| 230 | Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels | 1.3 | 25 | Citations (PDF) |
| 231 | Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy | 1.7 | 13 | Citations (PDF) |
| 232 | Molecular tests for breast-cancer diagnosis? | 27.4 | 0 | Citations (PDF) |
| 233 | The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer | 2.3 | 230 | Citations (PDF) |
| 234 | Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response | 2.3 | 149 | Citations (PDF) |
| 235 | Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples | 1.8 | 13 | Citations (PDF) |
| 236 | 256 CHECK: COHORT HIP AND COHORT KNEE; SIMILARITIES AND DIFFERENCES WITH THE OA INITIATIVE | 5.5 | 0 | Citations (PDF) |
| 237 | Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases | 3.7 | 59 | Citations (PDF) |
| 238 | Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary | 16.9 | 180 | Citations (PDF) |
| 239 | The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study | 2.3 | 110 | Citations (PDF) |
| 240 | Validation of 70-gene prognosis signature in node-negative breast cancer | 2.3 | 158 | Citations (PDF) |
| 241 | Increased risk of colorectal neoplasia in asymptomatic liver-transplant recipients | 16.8 | 11 | Citations (PDF) |
| 242 | Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus | 1.7 | 69 | Citations (PDF) |
| 243 | The insulin-like growth factor 1 receptor in cancer: Old focus, new future | 4.9 | 156 | Citations (PDF) |
| 244 | p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast | 1.6 | 42 | Citations (PDF) |
| 245 | Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) | 27.4 | 278 | Citations (PDF) |
| 246 | The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast | 3.6 | 23 | Citations (PDF) |
| 247 | The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma | 3.6 | 53 | Citations (PDF) |
| 248 | 244 AN UNIQUE EARLY OSTEOARTHRITIS COHORT OF HIP AND KNEE: THE CHECK STUDY | 5.5 | 0 | Citations (PDF) |
| 249 | 247 IMPACT OF COMORBIDITIES ON COMPLAINTS OF EARLY OSTEOARTHRITIS IN THE CHECK STUDY | 5.5 | 0 | Citations (PDF) |
| 250 | 256 RADIOLOGICAL FINDINGS IN A COHORT OF EARLY OSTEOARTHRITIS, THE CHECK STUDY | 5.5 | 0 | Citations (PDF) |
| 251 | Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the Breast | 2.3 | 44 | Citations (PDF) |
| 252 | High ICAM-1 gene expression in pulmonary fibroblasts of COPD patients: a reflection of an enhanced immunological function | 8.7 | 30 | Citations (PDF) |
| 253 | Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy | 3.7 | 236 | Citations (PDF) |
| 254 | Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells | 3.8 | 14 | Citations (PDF) |
| 255 | Tissue Distribution of the Death Ligand TRAIL and Its Receptors | 1.4 | 168 | Citations (PDF) |
| 256 | Axillary recurrence after sentinel lymph node biopsy | 0.9 | 30 | Citations (PDF) |
| 257 | Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes | 4.3 | 41 | Citations (PDF) |
| 258 | Neurological Outcome in School-Age Children After In Utero Exposure to Coumarins | 0.5 | 0 | Citations (PDF) |
| 259 | Coumarins during Pregnancy: Long-term Effects on Growth and Development of School-age Children | 4.1 | 114 | Citations (PDF) |
| 260 | Neurological outcome in school-age children after in utero exposure to coumarins | 1.9 | 37 | Citations (PDF) |
| 261 | In Utero Exposure to Coumarins and Cognition at 8 to 14 Years Old | 4.5 | 49 | Citations (PDF) |
| 262 | Growth until puberty after in utero exposure to coumarins | 0.5 | 19 | Citations (PDF) |
| 263 | Behavioural outcome of school-age children after prenatal exposure to coumarins | 1.9 | 10 | Citations (PDF) |
| 264 | Membrane-associated mucins | 0.1 | 0 | Citations (PDF) |
| 265 | Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation | 5.5 | 11 | Citations (PDF) |
| 266 | A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. | 2.5 | 370 | Citations (PDF) |
| 267 | Nucleus-associated phosphorylation of Ins(1,4,5)P3 to InsP6 in Dictyostelium | 3.8 | 24 | Citations (PDF) |
| 268 | Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. | 5.4 | 483 | Citations (PDF) |
| 269 | Is episialin/MUC1 involved in breast cancer progression? | 8.6 | 72 | Citations (PDF) |
| 270 | The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. | 5.4 | 64 | Citations (PDF) |
| 271 | Cause‐specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio‐economic status | 4.3 | 0 | Citations (PDF) |
| 272 | Abstract 7626: A gene expression classifier to predict progression risk of ductal carcinoma in situ to invasive breast cancer | 3.8 | 0 | Citations (PDF) |
